Abbott Laboratories (ABT) : The total negative money flow of $51.45 million on Thursday indicates selling on strength. The inflow of money on upticks was $50.47 million, compared to $101.92 million outflow on downticks, which confirms distribution in the stock. The up to down ratio was 0.5. The negative money flow of $47.77 million in block trades reveals that the informed traders sold the stock on every bit of price strength. The traded value of the stock on uptick was $21.48 million in a block trade.The transaction value of block trade on downtick was $69.25 million. The uptick to downtick ratio was 0.31. The price action in the Abbott Laboratories (ABT) stock suggests that both the bulls and the bears were in equilibrium. The stock traded at $42.28 with a gain of $0.31 , a change of 0.74% over the previous days close. The stock registered 0.93% for the week.
The stock has recorded a 20-day Moving Average of 8.2% and the 50-Day Moving Average is 9.78%. Shares have dropped -15.29% from its 1 Year high price. On Jul 23, 2015, the shares registered one year high at $51.74 and the one year low was seen on Jan 28, 2016. The 50-Day Moving Average price is $38.87 and the 200 Day Moving Average price is recorded at $39.97.
Abbott Laboratories (NYSE:ABT): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $42.34 and $42.02 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $42.42. The buying momentum continued till the end and the stock did not give up its gains. It closed at $42.28, notching a gain of 0.74% for the day. The total traded volume was 9,011,856 . The stock had closed at $41.97 on the previous day.
In an insider trading activity, Allen Hubert L, Officer (Executive Vice President) of ABBOTT LABORATORIES, unloaded 3,400 shares at an average price of $37.14 on June 28, 2016. The total amount of the transaction was worth $126,276, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products.